

Supplementary Table 6. LDL-C related endpoints after excluding patients who transiently or permanently discontinued study medications during the trial

Endpoints	ROS10/EZT10 (n=265)	ROS20 (n=243)	Odds ratio (95% confidence interval)	P
Primary endpoint				
LDL-C reduction $\geq 50\%$	195 (73.6)	143 (58.9)	1.948 (1.340–2.831)	0.0004
Secondary endpoints				
LDL-C <70 mg/dL	213 (80.4)	160 (65.9)	2.125 (1.420–3.179)	0.0002
LDL-C reduction $\geq 50\%$ or LDL-C <70 mg/dL	224 (84.5)	180 (74.1)	1.912 (1.232–2.968)	0.0035
Absolute LDL-C reduction (mg/dL)	73.6 \pm 37.0	66.1 \pm 34.6	-	0.0175
LDL-C reduction percentage	54.4 \pm 21.0	48.8 \pm 19.6	-	0.0021

Data are presented as n (%) or mean \pm standard deviation.
LDL-C, low-density lipoprotein cholesterol.

Supplementary Table 7. Any serious adverse events by MedDRA body system in the safety population

Body system	Number (%) of patients		P
	ROS10/EZT10 (n=295)	ROS20 (n=287)	
Total	22 (7.5)	22 (7.7)	0.9244
Cardiac disorders	1 (0.3)	3 (1.0)	
Gastrointestinal disorders	3 (1.0)	1 (0.4)	
General disorders and administration site conditions	2 (0.7)	6 (2.1)	
Hepatobiliary disorders	3 (1.0)	0 (0.0)	
Infections and infestations	2 (0.7)	1 (0.4)	
Injury, poisoning and procedural complications	1 (0.3)	0 (0.0)	
Investigations	1 (0.3)	0 (0.0)	
Musculoskeletal and connective tissue disorders	1 (0.3)	0 (0.0)	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	2 (0.7)	1 (0.4)	
Nervous system disorders	6 (2.0)	10 (3.5)	
Psychiatric disorders	1 (0.3)	0 (0.0)	
Renal and urinary disorders	1 (0.3)	0 (0.0)	
Other vascular disorders	1 (0.3)	0 (0.0)	

Medical Dictionary for Regulatory Activities (MedDRA) dictionary Version 21.1 (<https://www.meddra.org/>) was used for coding.

Supplementary Table 8. TEAEs by MedDRA body system in the safety population

Body system	Number (%) of patients		P
	ROS10/EZT10 (n=295)	ROS20 (n=287)	
Total*	11 (3.7)	9 (3.1)	0.6946
Gastrointestinal disorders	1 (0.3)	0 (0)	
General disorders and administration site conditions	4 (1.4)	1 (0.4)	
Investigations	5 (1.7)	5 (1.7)	
Musculoskeletal and connective tissue disorders	3 (1.0)	3 (1.1)	

Medical Dictionary for Regulatory Activities (MedDRA) dictionary Version 21.1 (<https://www.meddra.org/>) was used for coding. For patients who experienced TEAEs in 2 or more organ system, each event was counted for each organ system. Therefore, in the ROS10/EZT10 group, the sum of each number (=1+4+5+3) is greater than the total number of 11.

TEAE, treatment-emergent adverse event.

*Total numbers indicate the number of patients who experienced TEAEs, which differ the values of event numbers presented in Table 3 because several patients had >1 TEAEs.